Inectolizumab With Steroid Optimization in Newly Treated NMOSD

NCT07159893 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Neuromyelitis Optica
Autoimmune Diseases
Demyelinating Autoimmune Diseases, CNS

Interventions

DRUG: Inebilizumab + Rapid Steroid Tapering group
DRUG: Inebilizumab + Standard Steroid Tapering group

Sponsor

First Affiliated Hospital of Wenzhou Medical University